Case number 2016-2277
Indivior Inc. v. Dr. Reddy's Laboratories, S.A. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Feb 1, 2019 | 124 | Clerk's Letter to Appellants Dr. Reddy's Laboratories Inc. and Dr. Reddy's Laboratories, S.A. (Closed Case Letter Regarding Motion to Withdraw Counsel). See related entry: [123]. Service as of this date by the Clerk of Court. [582665] [JAL] [Entered: 02/01/2019 09:50 AM] (1) |
| Jan 30, 2019 | 123 | MOTION of Appellants Dr. Reddy's Laboratories Inc. and Dr. Reddy's Laboratories, S.A. to withdraw counsel John Coy Stull [Consent: unopposed]. Service: 01/30/2019 by email. [582208] [16-2277] [Kevin Martin] [Entered: 01/30/2019 04:04 PM] (4) |
| Jun 8, 2018 | 121 | NOTICE OF REJECTION: The Opening and Responsive Brief of Plaintiffs-Cross-Appellants [120] is not in compliance with the rules of this court and is therefore rejected for filing. Corrected brief due 06/22/2018. Appellants' response and reply briefs are due 07/16/2018. Service as of this date by the Clerk of Court. [527952] [MJL] [Entered: 06/08/2018 11:11 AM] (2) |
| Jun 8, 2018 | 122 | ORDER filed. The motion to dismiss appeals 16-2277, 16-2278, 16-2397, 16-2398, 18-1061, and 18-1119 pursuant to FRAP 42(b) [118] is granted and the mandate is issued. The revised official caption for 17-2587, 18-1010, -1058, -1062, -1114, -1115, -1176, -1177 is reflected in the order. - FOR CALENDAR. Service as of this date by the Clerk of Court. [528099] [16-2277, 16-2278, 16-2397, 16-2398, 18-1061, 18-1119, 17-2587, 18-1010, 18-1058, 18-1062, 18-1114, 18-1115, 18-1176, 18-1177] [MJL] [Entered: 06/08/2018 03:35 PM] (4) |
| Jun 4, 2018 | 120 | TENDERED from Cross-Appellants AQUESTIVE THERAPEUTICS, INC., Indivior Inc. and Indivior UK Limited. Title: RESPONSE BRIEF. Service: 06/04/2018 by email. [526786] [16-2277]. This brief has been rejected. See Doc. No. [121]. [Matthew Kudzin] [Entered: 06/04/2018 09:47 PM] (0) |
| May 30, 2018 | 119 | Entry of appearance for Sujatha Vathyam as of counsel for Cross-Appellants Indivior Inc. and Indivior UK Limited. Service: 05/30/2018 by clerk. [525600] [16-2277] [Sujatha Vathyam] [Entered: 05/30/2018 05:18 PM] (2) |
| May 25, 2018 | 118 | MOTION of Cross-Appellants Indivior Inc., Indivior UK Limited, AQUESTIVE THERAPEUTICS, INC. and Appellants Par Pharmaceutical, Inc. and IntelGenX Technologies Corp. to voluntarily dismiss appeal pursuant to FRAP 42(b). [Consent: unopposed]. Service: 05/25/2018 by clerk. [524838] [16-2277] [Daniel Ladow] [Entered: 05/25/2018 03:57 PM] (20) |
| May 21, 2018 | 117 | Notice of Rejection to Appellants IntelGenX Technologies Corp. and Par Pharmaceutical, Inc., the following document(s) cannot be filed: [116] party document. Reason(s) See notice for further details. [523079] [JB] [Entered: 05/21/2018 08:54 AM] (1) |
| May 18, 2018 | 116 | Stipulation of Voluntary Dismissal of Appeals and Cross-Appeals Involving Par Pharmaceutical, Inc. and Intelgenx Technologies Corp. for Cross-Appellants Indivior UK Limited, Indivior Inc. and AQUESTIVE THERAPEUTICS, INC.. Service: 05/18/2018 by clerk. [523049] [16-2277] This document has been rejected. See Doc No. [117] [Daniel Ladow] [Entered: 05/18/2018 06:41 PM] (0) |
| May 11, 2018 | 115 | Note to file: 18-1949 (COMP COMPANION started 05/11/2018) with 16-2277. These cases shall be considered companion cases and assigned to the same merits panel for oral argument. [520951] [18-1949, 16-2277] [CMP] [Entered: 05/11/2018 09:50 AM] (0) |
| Apr 26, 2018 | 114 | 6 paper copies of the Corrected Opening Brief [113] received from Appellants Actavis Laboratories UT, Inc., Teva Pharmaceuticals USA, Inc. and Watson Laboratories Inc. [517066] [JCP] [Entered: 04/26/2018 12:41 PM] (0) |
| Apr 23, 2018 | 112 | TENDERED from Appellants Watson Laboratories Inc., Actavis Laboratories UT, Inc. and Teva Pharmaceuticals USA, Inc.. Title: CORRECTED OPENING BRIEF. Service: 04/23/2018 by email. [515986] [16-2277] [Stephen Smerek] [Entered: 04/23/2018 10:59 AM] (409) |
| Apr 23, 2018 | 113 | CORRECTED BRIEF FILED for Appellants Actavis Laboratories UT, Inc., Teva Pharmaceuticals USA, Inc. and Watson Laboratories Inc. [112]. Number of Pages: 44. Service: 04/23/2018 by email. The paper copies of the brief should be received by the court on or before 05/01/2018. Cross-Appellants AQUESTIVE THERAPEUTICS, INC., Indivior Inc. and Indivior UK Limited brief is due 06/04/2018. [516322] [JB] [Entered: 04/24/2018 10:42 AM] (409) |
| Apr 20, 2018 | 111 | 6 paper copies of the Opening Brief [108] received from Appellants Dr. Reddy's Laboratories Inc. and Dr. Reddy's Laboratories, S.A. [515622] [JCP] [Entered: 04/20/2018 01:05 PM] (0) |
| Apr 17, 2018 | 110 | 6 paper copies of the Corrected Opening Brief [109] received from Appellants IntelGenX Technologies Corp. and Par Pharmaceutical, Inc. [514658] [JCP] [Entered: 04/18/2018 07:42 AM] (0) |
| Apr 16, 2018 | 107 | ORDER filed. The motion [103] [104] [105] is granted to the extent that the March 20, 2018 order is vacated in part. (1) Dr. Reddy's corrected opening brief filed on February 22, 2018 is accepted for filing, Par Pharma's corrected opening brief filed on February 26, 2018 is accepted for filing, and Watson is directed to file a corrected opening brief not to exceed 14,000 words—inclusive of words incorporated by reference—no later than five days from the date of filing of this order. (2) No later than 40 days from the date of filing of Watson's corrected opening brief, the cross-appellants are directed to file a joint principal and response brief not to exceed 20,500 words. (3) No later than 40 days after the filing of the cross-appellants joint principal and response brief, the appellants are directed to file individual response and reply briefs not to exceed 5,000 words each. (4) No later than 14 days thereafter, the cross-appellants are directed to file a joint reply brief not to exceed 9,000 words. Service: 04/16/2018 by clerk. [513513] [LMS] [Entered: 04/16/2018 09:28 AM] (3) |
| Apr 16, 2018 | 108 | CORRECTED BRIEF FILED for Appellants Dr. Reddy's Laboratories Inc. and Dr. Reddy's Laboratories, S.A. [90]. Number of Pages: 59. Service: 02/22/2018 by email. The paper copies of the brief should be received by the court on or before 04/23/2018. [513595] [JB] [Entered: 04/16/2018 11:31 AM] (347) |
| Apr 16, 2018 | 109 | CORRECTED BRIEF FILED for Appellants IntelGenX Technologies Corp. and Par Pharmaceutical, Inc. [96]. Number of Pages: 51. Service: 02/26/2018 by email. The paper copies of the brief should be received by the court on or before 04/23/2018. [513600] [JB] [Entered: 04/16/2018 11:44 AM] (219) |
| Apr 13, 2018 | 106 | RESPONSE of Cross-Appellants Indivior Inc., Indivior UK Limited and AQUESTIVE THERAPEUTICS, INC. to the motion [103] filed by Appellants Dr. Reddy's Laboratories Inc. and Dr. Reddy's Laboratories, S.A., motion [104] filed by Appellants IntelGenX Technologies Corp. and Par Pharmaceutical, Inc., motion [105] filed by Appellants Actavis Laboratories UT, Inc., Teva Pharmaceuticals USA, Inc. and Watson Laboratories Inc.. Service: 04/13/2018 by email. [513391] [16-2277] [Matthew Kudzin] [Entered: 04/13/2018 04:00 PM] (11) |
| Apr 3, 2018 | 103 | MOTION of Appellants Dr. Reddy's Laboratories Inc. and Dr. Reddy's Laboratories, S.A. to reconsider court order [101]. Response/Opposition is due 04/13/2018 [Consent: partial consent]. Service: 04/03/2018 by email. [510385] [16-2277]--[Edited 04/04/2018 by MJL to correct docket text]. [Kevin Martin] [Entered: 04/03/2018 05:14 PM] (18) |
| Apr 3, 2018 | 104 | MOTION of Appellants IntelGenX Technologies Corp. and Par Pharmaceutical, Inc. to reconsider court order [87], court order [101]. Response/Opposition is due 04/13/2018 [Consent: partial consent]. Service: 04/03/2018 by email. [510406] [16-2277]--[Edited 04/04/2018 by MJL to correct docket text]. [Robert Gajarsa] [Entered: 04/03/2018 05:36 PM] (15) |
| Apr 3, 2018 | 105 | MOTION of Appellants Actavis Laboratories UT, Inc., Teva Pharmaceuticals USA, Inc. and Watson Laboratories Inc. to reconsider court order [87], court order [101]. Response/Opposition is due 04/13/2018. [Consent: partial consent]. Service: 04/03/2018 by email. [510430] [16-2277]--[Edited 04/04/2018 by MJL to correct docket text]. [Stephen Smerek] [Entered: 04/03/2018 07:54 PM] (9) |
| Mar 20, 2018 | 101 | ORDER filed. The stay is lifted. The appellants' original briefs are stricken and will not be transmitted to the merits panel. The cross-appellants' motion [84] is denied. Within 60 days from the date of filing of this order, the appellants are directed to file a joint opening brief not to exceed 18,000 words. No later than 40 days thereafter, the cross-appellants are directed to file a joint principal and response brief not to exceed 20,500 words. No later than 40 days thereafter, the appellants are directed to file a joint response and reply brief not to exceed 18,000 words. No later than 14 days thereafter, the cross-appellants are directed to file a joint reply brief not to exceed 9,000 words. Service: 03/20/2018 by clerk. [506473] Vacated-in-part pursuant to the court's order. See Doc No. [107] [LMS] [Entered: 03/20/2018 09:31 AM] (3) |
| Mar 20, 2018 | 102 | Pursuant to the court's 3/20/2018 Order, the previously filed opening briefs [77], [76], [73], [72], [71], [70] in 16-2277 have been stricken. (See Order DE #101 for further details) [506753] [JB] [Entered: 03/20/2018 03:55 PM] (0) |
| Feb 28, 2018 | 97 | Amended Entry of appearance for James Francis Hibey as principal counsel for Cross-Appellant AQUESTIVE THERAPEUTICS, INC.. Service: 02/28/2018 by email. [501818] [James Hibey] [Entered: 02/28/2018 02:58 PM] (2) |
| Feb 28, 2018 | 98 | Amended Entry of appearance for Cassandra A. Adams as of counsel for Cross-Appellant AQUESTIVE THERAPEUTICS, INC.. Service: 02/28/2018 by email. [501820] [Cassandra Adams] [Entered: 02/28/2018 03:01 PM] (2) |
| Feb 28, 2018 | 99 | Amended Certificate of Interest for the Cross-Appellant AQUESTIVE THERAPEUTICS, INC.. Service: 02/28/2018 by email. [501823] [Jamie Lucia] [Entered: 02/28/2018 03:04 PM] (3) |
| Feb 28, 2018 | 100 | RESPONSE of Cross-Appellants AQUESTIVE THERAPEUTICS, INC., Indivior Inc. and Indivior UK Limited to the court order to show cause [87] ,court order [87]. Service: 02/28/2018 by email. [501894] [Robert Fowler] [Entered: 02/28/2018 05:55 PM] (15) |
| Feb 26, 2018 | 92 | Entry of appearance for Herman H. Yue as of counsel for Appellants IntelGenX Technologies Corp. and Par Pharmaceutical, Inc.. Service: 02/26/2018 by email. [501016] [Herman Yue] [Entered: 02/26/2018 01:08 PM] (3) |
| Feb 26, 2018 | 93 | RESPONSE of Appellants Actavis Laboratories UT, Inc., Teva Pharmaceuticals USA, Inc. and Watson Laboratories Inc. to the court order to show cause [87] ,court order [87]. Service: 02/26/2018 by email. [501157] [Michael Nutter] [Entered: 02/26/2018 04:30 PM] (13) |
| Feb 26, 2018 | 94 | RESPONSE of Appellants IntelGenX Technologies Corp. and Par Pharmaceutical, Inc. to the court order to show cause [87] ,court order [87]. Service: 02/26/2018 by email. [501216] [Robert Gajarsa] [Entered: 02/26/2018 08:17 PM] (5) |
| Feb 26, 2018 | 95 | Notice of Correction to the Brief Doc No. [72] for Appellants IntelGenX Technologies Corp. and Par Pharmaceutical, Inc.. Service: 02/26/2018 by email. [501217] [Daniel Brown] [Entered: 02/26/2018 08:24 PM] (4) |
| Feb 26, 2018 | 96 | TENDERED from Appellants IntelGenX Technologies Corp. and Par Pharmaceutical, Inc.. Title: CORRECTED OPENING BRIEF. Service: 02/26/2018 by email. [501218] [Daniel Brown] [Entered: 02/26/2018 08:30 PM] (219) |
| Feb 22, 2018 | 89 | Entry of appearance for Alexandra Lu as of counsel for Appellants Dr. Reddy's Laboratories Inc. and Dr. Reddy's Laboratories, S.A.. Service: 02/22/2018 by email. [500364] [Kevin Martin] [Entered: 02/22/2018 01:59 PM] (1) |
| Feb 22, 2018 | 90 | TENDERED from Appellants Dr. Reddy's Laboratories Inc. and Dr. Reddy's Laboratories, S.A.. Title: CORRECTED OPENING BRIEF. Service: 02/22/2018 by email. [500366] [Kevin Martin] [Entered: 02/22/2018 02:05 PM] (347) |
| Feb 22, 2018 | 91 | REMINDER: All counsel of record are reminded of their responsibility per Fed. Cir. R. 47.4(a)and Fed. Cir. R. 47.3 to promptly submit an amended Certificate of Interest (COI) and/or Entry of Appearance (EOA) as information changes during the pendency of the appeal. Failure to comply with these Rules may delay the timely processing of your case or result in adverse action. [500412] [JB] [Entered: 02/22/2018 03:29 PM] (0) |
| Feb 21, 2018 | 88 | Entry of appearance for Jamie Lucia as of counsel for Cross-Appellant AQUESTIVE THERAPEUTICS, INC.. Service: 02/21/2018 by email. [499917] [Jamie Lucia] [Entered: 02/21/2018 04:04 PM] (2) |
| Feb 20, 2018 | 87 | ORDER filed. The briefing schedule is stayed. Within five days from the date of filing of this order, the appellants are directed to either file corrected briefs or explain why their respective briefs should not be stricken for failing to comply with the court's rules. The court will hold the cross-appellants' motion [84] in abeyance until further consideration of the responses by the appellants. Service: 02/20/2018 by clerk. [499292] [LMS] [Entered: 02/20/2018 11:51 AM] (3) |
| Feb 6, 2018 | 86 | ORDER filed. The motions [82] [83] are granted. The revised official caption and short caption are reflected in the order. Service: 02/06/2018 by clerk. [495559] [LMS] [Entered: 02/06/2018 01:19 PM] (2) |
| Feb 1, 2018 | 85 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: re: ERROR: Motion to modify the official caption [82] did not include a certificate of compliance. CORRECTION: Pursuant to FRAP 32(g)(1), motions require a certificate of compliance with the word count. Please ensure future motions include the certificate of compliance. THIS MESSAGE IS FOR INFORMATIONAL PURPOSES ONLY. [494290] [JB] [Entered: 02/01/2018 09:40 AM] (0) |
| Jan 30, 2018 | 83 | MOTION of Cross-Appellants Indivior Inc., Indivior UK Limited and MonoSol Rx, LLC to extend the time to 03/26/2018 at 11:59 pm to file the appellee/respondent/cross-appellant's principal brief. Any response is due within 10 days of service [Consent: unopposed]. Service: 01/30/2018 by email. [493858] [Robert Fowler] [Entered: 01/30/2018 09:58 PM] (15) |
| Jan 30, 2018 | 84 | MOTION of Cross-Appellants Indivior Inc., Indivior UK Limited and MonoSol Rx, LLC to waive the requirements regarding the brief (to file extended brief pursuant to Fed. Cir. R> 28(c)). Any response is due within 10 days of service [Consent: unopposed]. Service: 01/30/2018 by email. [493859] [Robert Fowler] [Entered: 01/30/2018 10:09 PM] (13) |
| Jan 29, 2018 | 82 | MOTION of to modify the official caption. Any response is due within 10 days of service [Consent: unopposed]. Service: 01/29/2018 by email. [493471] [Cassandra Adams] [Entered: 01/29/2018 04:25 PM] (15) |
| Jan 24, 2018 | 81 | 6 paper copies of the Opening Brief [73] received from Appellants Dr. Reddy's Laboratories Inc. and Dr. Reddy's Laboratories, S.A.. [492262] [CFT] [Entered: 01/24/2018 10:57 AM] (0) |
| Jan 22, 2018 | 80 | 6 paper copies of the Opening Brief [76] received from Appellants Actavis Laboratories UT, Inc., Teva Pharmaceuticals USA, Inc. and Watson Laboratories Inc. [491287] [SJL] [Entered: 01/22/2018 10:26 AM] (0) |
| Jan 19, 2018 | 78 | Note to file: 18-1405 (COMPANION started 01/19/2018) with 16-2277. These cases shall be considered companion cases and assigned to the same merits panel for oral argument. [490899] [16-2277, 18-1405] [MJL] [Entered: 01/19/2018 11:35 AM] (0) |
| Jan 19, 2018 | 79 | 6 paper copies of the Opening Brief [77] received from Appellants IntelGenX Technologies Corp. and Par Pharmaceutical, Inc. [491195] [SJL] [Entered: 01/22/2018 08:36 AM] (0) |
| Jan 17, 2018 | 74 | This entry was made in error and has been removed from the docket. NOTICE OF REJECTION: The brief of Appellants Actavis Laboratories UT, Inc., Teva Pharmaceuticals USA, Inc. and Watson Laboratories Inc., Brief of Appellants [71], is not in compliance with the rules of this court and is therefore rejected for filing. Service as of this date by Clerk of Court. [490429]--[Edited 01/18/2018 by clerk to indicate entry made in error] [CMP] [Entered: 01/17/2018 03:37 PM] (0) |
| Jan 17, 2018 | 75 | This entry was made in error and has been removed from the docket. NOTICE OF REJECTION: The brief of Appellants IntelGenX Technologies Corp. and Par Pharmaceutical, Inc., Brief of Appellants [72], is not in compliance with the rules of this court and is therefore rejected for filing. Service as of this date by Clerk of Court. [490447]--[Edited 01/18/2018 by clerk to indicate entry made in error] [CMP] [Entered: 01/17/2018 04:02 PM] (0) |
| Jan 16, 2018 | 66 | Amended Certificate of Interest for the Appellants Actavis Laboratories UT, Inc., Teva Pharmaceuticals USA, Inc. and Watson Laboratories Inc.. Service: 01/16/2018 by email. [489841] [Michael Nutter] [Entered: 01/16/2018 03:41 PM] (5) |
| Jan 16, 2018 | 67 | Amended Certificate of Interest for the Appellant IntelGenX Technologies Corp.. Service: 01/16/2018 by email. [489845] [Daniel Brown] [Entered: 01/16/2018 03:42 PM] (4) |
| Jan 16, 2018 | 68 | Amended Certificate of Interest for the Appellant Par Pharmaceutical, Inc.. Service: 01/16/2018 by email. [489848] [Daniel Brown] [Entered: 01/16/2018 03:46 PM] (4) |
| Jan 16, 2018 | 69 | Amended Certificate of Interest for the Appellants Dr. Reddy's Laboratories Inc. and Dr. Reddy's Laboratories, S.A.. Service: 01/16/2018 by email. [489968] [Kevin Martin] [Entered: 01/16/2018 05:04 PM] (3) |
| Jan 16, 2018 | 70 | TENDERED from Appellants Dr. Reddy's Laboratories Inc. and Dr. Reddy's Laboratories, S.A.. Title: OPENING BRIEF. Service: 01/16/2018 by email. [489975] This brief has been stricken. (See Order DE #101). [Kevin Martin] [Entered: 01/16/2018 05:11 PM] (0) |
| Jan 16, 2018 | 71 | TENDERED from Appellants Actavis Laboratories UT, Inc., Teva Pharmaceuticals USA, Inc. and Watson Laboratories Inc.. Title: OPENING BRIEF. Service: 01/16/2018 by email. [490044] This brief has been stricken. (See Order DE #101). [Michael Nutter] [Entered: 01/16/2018 06:46 PM] (0) |
| Jan 16, 2018 | 72 | TENDERED from Appellants IntelGenX Technologies Corp. and Par Pharmaceutical, Inc.. Title: OPENING BRIEF. Service: 01/16/2018 by email. [490045] This brief has been stricken. (See Order DE #101). [Daniel Brown] [Entered: 01/16/2018 06:47 PM] (0) |
| Jan 16, 2018 | 73 | BRIEF FILED for Appellants Dr. Reddy's Laboratories Inc. and Dr. Reddy's Laboratories, S.A. [70]. Number of Pages: 60. Service: 01/16/2018 by email. The paper copies of the brief should be received by the court on or before 01/24/2018. Cross-Appellants Indivior Inc., Indivior UK Limited and MonoSol Rx, LLC brief is due 02/26/2018. [490421] This brief has been stricken. (See Order DE #101). [CMP] [Entered: 01/17/2018 03:33 PM] (0) |
| Jan 16, 2018 | 76 | BRIEF FILED for Appellants Actavis Laboratories UT, Inc., Teva Pharmaceuticals USA, Inc. and Watson Laboratories Inc. [71]. Number of Pages: 55. Service: 01/16/2018 by email. The paper copies of the brief should be received by the court on or before 01/25/2018. Cross-Appellants Indivior Inc., Indivior UK Limited and MonoSol Rx, LLC brief is due 02/26/2018. [490659] This brief has been stricken. (See Order DE #101). [CMP] [Entered: 01/18/2018 12:00 PM] (0) |
| Jan 16, 2018 | 77 | BRIEF FILED for Appellants IntelGenX Technologies Corp. and Par Pharmaceutical, Inc. [72]. Number of Pages: 51. Service: 01/16/2018 by email. The paper copies of the brief should be received by the court on or before 01/25/2018. Cross-Appellants Indivior Inc., Indivior UK Limited and MonoSol Rx, LLC brief is due 02/26/2018. [490661] This brief has been stricken. (See Order DE #101). [CMP] [Entered: 01/18/2018 12:03 PM] (0) |
| Nov 30, 2017 | 64 | NOTE TO FILE: FOR PRIOR ENTRIES SEE 18-1176 . [479183] [JB] [Entered: 11/30/2017 10:13 AM] (0) |
| Nov 30, 2017 | 65 | Entry of appearance for Beth S. Brinkmann as of counsel for Cross-Appellants Indivior Inc. and Indivior UK Limited. Service: 11/30/2017 by email. [479327] [Matthew Kudzin] [Entered: 11/30/2017 02:25 PM] (2) |
| Nov 29, 2017 | 61 | ORDER consolidating appeals; modifying the official caption. Appellants' brief(s) due 01/16/2018. Service as of this date by Clerk of Court. [478909] [16-2277, 18-1176] [SJ] [Entered: 11/29/2017 01:18 PM] (2) |
| Nov 29, 2017 | 62 | Note to file: The following cases are associated:16-2277 (lead) with 18-1176 (cross). FURTHER ENTRIES WILL BE ADDED TO THE LEAD APPEAL ONLY. [478916] [16-2277, 18-1176] [SJ] [Entered: 11/29/2017 01:36 PM] (0) |
| Nov 29, 2017 | 63 | Notice from Cross-Appellants Indivior Inc. and Indivior UK Limited regarding postjudgment motions. Service: 11/29/2017 by email. [479088] [Jeffrey Elikan] [Entered: 11/29/2017 04:48 PM] (20) |
| Nov 20, 2017 | 60 | Amended Certificate of Interest for the Appellants Actavis Laboratories UT, Inc. and Watson Laboratories Inc.. Service: 11/20/2017 by email. [477064] [George Lombardi] [Entered: 11/20/2017 02:43 PM] (5) |
| Nov 17, 2017 | 59 | Entry of appearance for Jason P. Hamilton as of counsel for Appellants Actavis Laboratories UT, Inc. and Watson Laboratories Inc.. Service: 11/17/2017 by email. [476506] [Jason Hamilton] [Entered: 11/17/2017 10:59 AM] (2) |
| Nov 16, 2017 | 58 | Amended Docketing Statement for the Appellants Dr. Reddy's Laboratories Inc. and Dr. Reddy's Laboratories, S.A.. Service: 11/16/2017 by email. [476135] [Kevin Martin] [Entered: 11/16/2017 12:01 PM] (5) |
| Nov 14, 2017 | 57 | Amended Docketing Statement for the Appellants IntelGenX Technologies Corp. and Par Pharmaceutical, Inc.. Service: 11/14/2017 by email. [475321] [Daniel Brown] [Entered: 11/14/2017 12:57 PM] (5) |
| Nov 13, 2017 | 51 | Amended Docketing Statement for the Cross-Appellants RB Pharmaceuticals Limited and Reckitt Benckiser Pharmaceuticals Inc.. Service: 11/13/2017 by clerk. [475015] [Daniel Ladow] [Entered: 11/13/2017 05:04 PM] (6) |
| Nov 13, 2017 | 52 | Amended Docketing Statement for the Cross-Appellants RB Pharmaceuticals Limited and Reckitt Benckiser Pharmaceuticals Inc.. Service: 11/13/2017 by clerk. [475017] [Daniel Ladow] [Entered: 11/13/2017 05:06 PM] (6) |
| Nov 13, 2017 | 53 | Amended Docketing Statement for the Cross-Appellants RB Pharmaceuticals Limited and Reckitt Benckiser Pharmaceuticals Inc.. Service: 11/13/2017 by clerk. [475018] [Daniel Ladow] [Entered: 11/13/2017 05:08 PM] (6) |
| Nov 13, 2017 | 54 | Amended Docketing Statement for the Cross-Appellant MonoSol Rx, LLC. Service: 11/13/2017 by email. [475054] [Cassandra Adams] [Entered: 11/13/2017 07:40 PM] (6) |
| Nov 13, 2017 | 55 | Amended Docketing Statement for the Cross-Appellant MonoSol Rx, LLC. Service: 11/13/2017 by email. [475056] [Cassandra Adams] [Entered: 11/13/2017 07:41 PM] (6) |
| Nov 13, 2017 | 56 | Amended Docketing Statement for the Cross-Appellant MonoSol Rx, LLC. Service: 11/13/2017 by email. [475058] [Cassandra Adams] [Entered: 11/13/2017 07:42 PM] (6) |
| Nov 3, 2017 | 50 | NOTE TO FILE: FOR PRIOR ENTRIES SEE 18-1058. [472710] [JB] [Entered: 11/03/2017 08:13 AM] (0) |
| Nov 1, 2017 | 48 | ORDER consolidating appeals (16-2277 (Lead) with 16-2278, 16-2397, 16-2398, 17-2587, 18-1010, 18-1058, 18-1061, 18-1062, 18-1114, 18-1115, 18-1119 (Members)). These appeals are consolidated. The revised official caption is reflected above. The appeallants' opening briefs are due no late than December 15, 2017. Service as of this date by Clerk of Court. [472356] [JB] [Entered: 11/01/2017 04:07 PM] (2) |
| Nov 1, 2017 | 49 | Note to file: The following cases are consolidated:16-2277 (Lead) with 16-2278, 16-2397, 16-2398, 17-2587, 18-1010, 18-1058, 18-1061, 18-1062, 18-1114, 18-1115, 18-1119 (Members). FURTHER ENTRIES WILL BE ADDED TO THE LEAD APPEAL ONLY. [472364] [JB] [Entered: 11/01/2017 04:22 PM] (0) |
| Oct 17, 2017 | 37 | Entry of appearance for George C. Lombardi as principal counsel for Appellants Actavis Laboratories UT, Inc. and Watson Laboratories Inc.. Service: 10/17/2017 by email. [468554] [George Lombardi] [Entered: 10/17/2017 04:09 PM] (2) |
| Oct 17, 2017 | 38 | Certificate of Interest for the Appellants Actavis Laboratories UT, Inc. and Watson Laboratories Inc.. Service: 10/17/2017 by email. [468561] [George Lombardi] [Entered: 10/17/2017 04:13 PM] (5) |
| Oct 17, 2017 | 39 | Docketing Statement for the Appellants Actavis Laboratories UT, Inc. and Watson Laboratories Inc.. Service: 10/17/2017 by email. [468567] [George Lombardi] [Entered: 10/17/2017 04:15 PM] (4) |
| Oct 17, 2017 | 40 | Entry of appearance for Geoffrey P. Eaton as of counsel for Appellants Actavis Laboratories UT, Inc. and Watson Laboratories Inc.. Service: 10/17/2017 by email. [468576] [Geoffrey Eaton] [Entered: 10/17/2017 04:22 PM] (2) |
| Oct 17, 2017 | 41 | Entry of appearance for Tyler G. Johannes as of counsel for Appellants Actavis Laboratories UT, Inc. and Watson Laboratories Inc.. Service: 10/17/2017 by email. [468592] [Tyler Johannes] [Entered: 10/17/2017 04:32 PM] (2) |
| Oct 17, 2017 | 42 | Entry of appearance for Michael K. Nutter as of counsel for Appellants Actavis Laboratories UT, Inc. and Watson Laboratories Inc.. Service: 10/17/2017 by email. [468598] [Michael Nutter] [Entered: 10/17/2017 04:38 PM] (2) |
| Oct 17, 2017 | 43 | Entry of appearance for Stephen R. Smerek as of counsel for Appellants Actavis Laboratories UT, Inc. and Watson Laboratories Inc.. Service: 10/17/2017 by email. [468616] [Stephen Smerek] [Entered: 10/17/2017 06:14 PM] (2) |
| Oct 17, 2017 | 44 | Docketing Statement for the Cross-Appellants RB Pharmaceuticals Limited and Reckitt Benckiser Pharmaceuticals Inc.. Service: 10/17/2017 by clerk. [468634] [Daniel Ladow] [Entered: 10/17/2017 08:49 PM] (6) |
| Oct 17, 2017 | 45 | Amended Certificate of Interest for the Cross-Appellants RB Pharmaceuticals Limited and Reckitt Benckiser Pharmaceuticals Inc.. Service: 10/17/2017 by clerk. [468635] [Daniel Ladow] [Entered: 10/17/2017 08:53 PM] (5) |
| Oct 17, 2017 | 46 | Docketing Statement for the Cross-Appellant MonoSol Rx, LLC. Service: 10/17/2017 by email. [468646] [Cassandra Adams] [Entered: 10/17/2017 10:14 PM] (6) |
| Oct 17, 2017 | 47 | Certificate of Interest for the Cross-Appellant MonoSol Rx, LLC. Service: 10/17/2017 by email. [468647] [Cassandra Adams] [Entered: 10/17/2017 10:16 PM] (3) |
| Oct 4, 2017 | 36 | Note to file: The following cases are associated:16-2277(Lead) with 18-1010 (Cross-Appeal). FURTHER ENTRIES WILL BE ADDED TO THE LEAD APPEAL ONLY. [465512] [JB] [Entered: 10/04/2017 12:45 PM] (0) |
| Oct 3, 2017 | 35 | ORDER filed. The appeals are reactivated. Appellants' opening briefs are due within 60 days of the date of this order. Service as of this date by Clerk of Court. [465242] [16-2277, 16-2278, 16-2397, 16-2398, 17-2587] [JB] [Entered: 10/03/2017 03:24 PM] (2) |
| Sep 29, 2017 | 33 | RESPONSE of Appellants IntelGenX Technologies Corp. and Par Pharmaceutical, Inc. to the clerk order to terminate appeal [29] ,clerk order [29]. Service: 09/29/2017 by email. [464392] [Daniel Brown] [Entered: 09/29/2017 02:21 PM] (1) |
| Sep 29, 2017 | 34 | Amended Notice of Appeal for Par Pharmaceutical, Inc. and IntelGenx Technologies Corp. Service: 09/28/2017 by email. [464414] [JB] [Entered: 09/29/2017 02:39 PM] (64) |
| Sep 25, 2017 | 31 | Note to file: The following cases are associated:16-2277 Lead with 17-2587 Consolidated. FURTHER ENTRIES WILL BE ADDED TO THE LEAD APPEAL ONLY. [463154] [JB] [Entered: 09/25/2017 09:56 AM] (0) |
| Sep 25, 2017 | 32 | Official caption revised to add consolidated appeal docketed on 9/25/17. The official caption is reflected on the electronic docket under the listing of the parties and counsel. Service as of this date by Clerk of Court. [463157] [JB] [Entered: 09/25/2017 09:58 AM] (0) |
| Aug 4, 2016 | 29 | ORDER filed. Appeals 2016-2277,-2278, - 2397, and -2398 are deactivated. Within 30 days of the district court’s ruling on the appellants’ Rule 52(b) and 59 motion, the parties are directed to inform this court how they believe these appeals should proceed. Service: 08/04/2016 by clerk. [356093] [16-2277, 16-2278, 16-2397, 16-2398] [NL] [Entered: 08/04/2016 09:54 AM] (2) |
| Aug 4, 2016 | 30 | Transcript Purchase Order Form for the Appellants IntelGenX Technologies Corp. and Par Pharmaceutical Inc. indicating that a request is made to the reporter for a transcript. Service: 08/04/2016 by email. [356167] [JB] [Entered: 08/04/2016 12:49 PM] (2) |
| Aug 3, 2016 | 28 | Transcript Purchase Order Form for the Appellants IntelGenX Technologies Corp. and Par Pharmaceutical Inc. indicating that a request is made to the reporter for a transcript. Service: 08/02/2013 by email. [355699] [JB] [Entered: 08/03/2016 10:15 AM] (1) |
| Jul 28, 2016 | 26 | Note to file: The following cases are associated: 16-2277 Lead with 16-2397 and 16-2398 Cross-Appeals. FURTHER ENTRIES WILL BE ADDED TO THE LEAD APPEAL ONLY. [354437] [JB] [Entered: 07/28/2016 04:08 PM] (0) |
| Jul 28, 2016 | 27 | Official caption revised to add two cross-appeals docketed on 7/28/2016. The official caption is reflected on the electronic docket under the listing of the parties and counsel. Service as of this date by Clerk of Court. [354441] [JB] [Entered: 07/28/2016 04:25 PM] (0) |
| Jul 21, 2016 | 25 | Notice from Appellants IntelGenX Technologies Corp. and Par Pharmaceutical Inc. regarding postjudgment motions. Service: 07/21/2016 by email. [352767] [Daniel Brown] [Entered: 07/21/2016 05:44 PM] (16) |
| Jul 19, 2016 | 24 | Entry of appearance for Jennifer Koh as of counsel for Appellants IntelGenX Technologies Corp. and Par Pharmaceutical Inc.. Service: 07/19/2016 by email. [352027] [Jennifer Koh] [Entered: 07/19/2016 03:13 PM] (3) |
| Jul 14, 2016 | 3 | Entry of appearance for Daniel G. Brown as principal counsel for Appellants IntelGenX Technologies Corp. and Par Pharmaceutical Inc.. Service: 07/14/2016 by email. [350936] [Daniel Brown] [Entered: 07/14/2016 06:01 PM] (3) |
| Jul 14, 2016 | 4 | Certificate of Interest for the Appellant Par Pharmaceutical Inc.. Service: 07/14/2016 by email. [350940] [Daniel Brown] [Entered: 07/14/2016 06:06 PM] (3) |
| Jul 14, 2016 | 5 | Certificate of Interest for the Appellant IntelGenX Technologies Corp.. Service: 07/14/2016 by email. [350941] [Daniel Brown] [Entered: 07/14/2016 06:12 PM] (3) |
| Jul 14, 2016 | 6 | Docketing Statement for the Appellants IntelGenX Technologies Corp. and Par Pharmaceutical Inc.. Service: 07/14/2016 by email. [350942] [Daniel Brown] [Entered: 07/14/2016 06:15 PM] (5) |
| Jul 14, 2016 | 7 | Entry of appearance for Gabriel K. Bell as of counsel for Appellants IntelGenX Technologies Corp. and Par Pharmaceutical Inc.. Service: 07/14/2016 by email. [350944] [Gabriel Bell] [Entered: 07/14/2016 06:20 PM] (3) |
| Jul 14, 2016 | 8 | Entry of appearance for Robert J. Gajarsa as of counsel for Appellants IntelGenX Technologies Corp. and Par Pharmaceutical Inc.. Service: 07/14/2016 by email. [350945] [Robert Gajarsa] [Entered: 07/14/2016 06:23 PM] (3) |
| Jul 14, 2016 | 9 | Entry of appearance for James Francis Hibey as principal counsel for Appellee MonoSol Rx, LLC. Service: 07/14/2016 by email. [350975] [James Hibey] [Entered: 07/14/2016 07:28 PM] (2) |
| Jul 14, 2016 | 10 | Entry of appearance for Cassandra A. Adams as of counsel for Appellee MonoSol Rx, LLC. Service: 07/14/2016 by email. [350976] [Cassandra Adams] [Entered: 07/14/2016 07:42 PM] (2) |
| Jul 14, 2016 | 11 | Certificate of Interest for the Appellee MonoSol Rx, LLC. Service: 07/14/2016 by email. [350977] [Cassandra Adams] [Entered: 07/14/2016 07:43 PM] (3) |
| Jul 14, 2016 | 12 | Docketing Statement for the Appellee MonoSol Rx, LLC. Service: 07/14/2016 by email. [350978] [Cassandra Adams] [Entered: 07/14/2016 07:45 PM] (4) |
| Jul 14, 2016 | 13 | Entry of appearance for Jeffrey B. Elikan as of counsel for Appellees RB Pharmaceuticals Limited and Reckitt Benckiser Pharmaceuticals Inc.. Service: 07/14/2016 by email. [350982] [Jeffrey Elikan] [Entered: 07/14/2016 08:06 PM] (2) |
| Jul 14, 2016 | 14 | This entry was made in error and has been removed from the docket. Entry of appearance for Daniel A. Ladow as principal counsel for Appellee Reckitt Benckiser Pharmaceuticals Inc.. Service: 07/14/2016 by email. [350983] [Daniel Ladow] [Entered: 07/14/2016 08:09 PM] (0) |
| Jul 14, 2016 | 15 | Docketing Statement for the Appellees RB Pharmaceuticals Limited and Reckitt Benckiser Pharmaceuticals Inc.. Service: 07/14/2016 by email. [350985] [Jeffrey Elikan] [Entered: 07/14/2016 08:10 PM] (4) |
| Jul 14, 2016 | 16 | Entry of appearance for Jeffrey H. Lerner as of counsel for Appellees RB Pharmaceuticals Limited and Reckitt Benckiser Pharmaceuticals Inc.. Service: 07/14/2016 by email. [350988] [Jeffrey Lerner] [Entered: 07/14/2016 08:13 PM] (2) |
| Jul 14, 2016 | 17 | Entry of appearance for Erica N. Andersen as of counsel for Appellees RB Pharmaceuticals Limited and Reckitt Benckiser Pharmaceuticals Inc.. Service: 07/14/2016 by email. [350991] [Erica Andersen] [Entered: 07/14/2016 08:17 PM] (2) |
| Jul 14, 2016 | 18 | Entry of appearance for Daniel A. Ladow as principal counsel for Appellees RB Pharmaceuticals Limited and Reckitt Benckiser Pharmaceuticals Inc.. Service: 07/14/2016 by email. [350992] [Daniel Ladow] [Entered: 07/14/2016 08:22 PM] (2) |
| Jul 14, 2016 | 19 | Certificate of Interest for the Appellees RB Pharmaceuticals Limited and Reckitt Benckiser Pharmaceuticals Inc.. Service: 07/14/2016 by email. [350993] [Daniel Ladow] [Entered: 07/14/2016 08:24 PM] (4) |
| Jul 14, 2016 | 20 | Entry of appearance for Timothy P. Heaton as of counsel for Appellees RB Pharmaceuticals Limited and Reckitt Benckiser Pharmaceuticals Inc.. Service: 07/14/2016 by email. [350994] [Timothy Heaton] [Entered: 07/14/2016 08:29 PM] (2) |
| Jul 14, 2016 | 21 | Entry of appearance for James M. Bollinger as of counsel for Appellees RB Pharmaceuticals Limited and Reckitt Benckiser Pharmaceuticals Inc.. Service: 07/14/2016 by email. [350995] [James Bollinger] [Entered: 07/14/2016 08:33 PM] (2) |
| Jul 14, 2016 | 22 | Entry of appearance for Magnus Essunger as of counsel for Appellees RB Pharmaceuticals Limited and Reckitt Benckiser Pharmaceuticals Inc.. Service: 07/14/2016 by email. [350997] [Magnus Essunger] [Entered: 07/14/2016 08:40 PM] (2) |
| Jul 14, 2016 | 23 | Entry of appearance for Charanjit Brahma as of counsel for Appellees RB Pharmaceuticals Limited and Reckitt Benckiser Pharmaceuticals Inc.. Service: 07/14/2016 by email. [350998] [Charanjit Brahma] [Entered: 07/14/2016 08:44 PM] (2) |
| Jun 30, 2016 | 1 | Appeal docketed. Received: 06/29/2016. [347695]Entry of Appearance due 07/14/2016. Certificate of Interest is due on 07/14/2016. Docketing Statement due 07/14/2016. Appellant/Petitioner's brief is due 08/29/2016. [JB] [Entered: 06/30/2016 11:46 AM] (58) |
| Jun 30, 2016 | 2 | Note to file: The following cases are associated:16-2277 Lead with 16-2278 Consolidated. FURTHER ENTRIES WILL BE ADDED TO THE LEAD APPEAL ONLY. [347726] [16-2277, 16-2278] [JB] [Entered: 06/30/2016 12:30 PM] (0) |
